The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma

D. Liebner
DOI: https://doi.org/10.1002/jso.23866
2015-04-01
Journal of Surgical Oncology
Abstract:Conventional chemotherapy can have a favorable impact on the natural history of disease for selected patients with primary high‐risk bone and soft‐tissue sarcomas. In particular, multidrug regimens are integral to the care of patients with the most aggressive histologies, including Ewing sarcoma, osteosarcoma, and non‐pleomorphic rhabdomyosarcoma. Appropriately selected patients with high‐risk, clinically localized soft‐tissue sarcomas may also benefit from histology‐tailored adjuvant or neoadjuvant therapy. For patients with recurrent disease, conventional chemotherapy is frequently the most appropriate first‐line therapy; active drugs are discussed at length. Several new promising cytotoxic chemotherapeutic agents are currently under development, including aldoxorubicin, TH‐302, and trabectedin. J. Surg. Oncol. 2015 111:622–631. © 2015 Wiley Periodicals, Inc.
What problem does this paper attempt to address?